Yarvitan

RSS

Withdrawn

This medicine's authorisation has been withdrawn

mitratapide
MedicineVeterinaryWithdrawn

Irish is available via eTranslation, the European Commission's machine translation service.

Translate to Irish | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for this product has been withdrawn at the request of the marketing authorisation holder.

español (ES) (256.72 KB - PDF)

Amharc

čeština (CS) (393.52 KB - PDF)

Amharc

dansk (DA) (256.17 KB - PDF)

Amharc

Deutsch (DE) (257.38 KB - PDF)

Amharc

eesti (ET) (255.5 KB - PDF)

Amharc

ελληνικά (EL) (454.41 KB - PDF)

Amharc

français (FR) (257.52 KB - PDF)

Amharc

italiano (IT) (256.43 KB - PDF)

Amharc

latviešu (LV) (399.71 KB - PDF)

Amharc

lietuvių (LT) (373.07 KB - PDF)

Amharc

magyar (HU) (384.35 KB - PDF)

Amharc

Nederlands (NL) (256.77 KB - PDF)

Amharc

polski (PL) (403.94 KB - PDF)

Amharc

português (PT) (257.16 KB - PDF)

Amharc

slovenčina (SK) (389.05 KB - PDF)

Amharc

slovenščina (SL) (380.7 KB - PDF)

Amharc

suomi (FI) (255.8 KB - PDF)

Amharc

svenska (SV) (256.06 KB - PDF)

Amharc

Product information

български (BG) (876.69 KB - PDF)

Amharc

español (ES) (368.06 KB - PDF)

Amharc

čeština (CS) (682.61 KB - PDF)

Amharc

dansk (DA) (413.04 KB - PDF)

Amharc

Deutsch (DE) (363.22 KB - PDF)

Amharc

eesti (ET) (360.22 KB - PDF)

Amharc

ελληνικά (EL) (926.55 KB - PDF)

Amharc

français (FR) (369.55 KB - PDF)

Amharc

italiano (IT) (358.34 KB - PDF)

Amharc

latviešu (LV) (723.79 KB - PDF)

Amharc

lietuvių (LT) (500.34 KB - PDF)

Amharc

magyar (HU) (667.24 KB - PDF)

Amharc

Malti (MT) (707.97 KB - PDF)

Amharc

Nederlands (NL) (359.17 KB - PDF)

Amharc

polski (PL) (707.86 KB - PDF)

Amharc

português (PT) (369.01 KB - PDF)

Amharc

română (RO) (511.36 KB - PDF)

Amharc

slovenčina (SK) (679.07 KB - PDF)

Amharc

slovenščina (SL) (667.27 KB - PDF)

Amharc

suomi (FI) (355.26 KB - PDF)

Amharc

svenska (SV) (366.58 KB - PDF)

Amharc
Latest procedure affecting product information:II/0003
20/10/2008

български (BG) (312.24 KB - PDF)

Amharc

español (ES) (232.03 KB - PDF)

Amharc

čeština (CS) (307.25 KB - PDF)

Amharc

dansk (DA) (233.01 KB - PDF)

Amharc

Deutsch (DE) (235.26 KB - PDF)

Amharc

eesti (ET) (231.11 KB - PDF)

Amharc

ελληνικά (EL) (308.87 KB - PDF)

Amharc

français (FR) (231.59 KB - PDF)

Amharc

italiano (IT) (231.31 KB - PDF)

Amharc

latviešu (LV) (309.08 KB - PDF)

Amharc

lietuvių (LT) (262.26 KB - PDF)

Amharc

magyar (HU) (304.77 KB - PDF)

Amharc

Malti (MT) (309.64 KB - PDF)

Amharc

Nederlands (NL) (234.5 KB - PDF)

Amharc

polski (PL) (274.42 KB - PDF)

Amharc

português (PT) (231.94 KB - PDF)

Amharc

română (RO) (295.75 KB - PDF)

Amharc

slovenčina (SK) (306.51 KB - PDF)

Amharc

slovenščina (SL) (304.86 KB - PDF)

Amharc

suomi (FI) (231.26 KB - PDF)

Amharc

svenska (SV) (231.79 KB - PDF)

Amharc

Product details

Name of medicine
Yarvitan
Active substance
mitratapide
International non-proprietary name (INN) or common name
mitratapide
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) code
QA08AB90

Pharmacotherapeutic group

Antiobesity preparations, excl. diet products

Therapeutic indication

As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight management programme which also includes appropriate dietary changes. Introducing appropriate lifestyle changes (e.g. increased exercise), in conjunction with this weight management programme, may provide additional benefits.

Authorisation details

EMA product number
EMEA/V/C/000113
Marketing authorisation holder
Janssen Pharmaceutica N.V.

Turnhoutseweg 30
B-2340 Beerse
Belgium

Marketing authorisation issued
14/11/2006
Revision
3

Assessment history

This page was last updated on

Share this page